Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Kristin C. Hicks; Paul L. Chariou; Yohei Ozawa; Christine M. Minnar; Karin M. Knudson; Thomas J. Meyer; Jing Bian; Margaret Cam; Jeffrey Schlom; Sofia R. Gameiro

doi:10.1038/s41467-021-25393-x

Nature Communications (Aug 2021)

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Kristin C. Hicks,
Paul L. Chariou,
Yohei Ozawa,
Christine M. Minnar,
Karin M. Knudson,
Thomas J. Meyer,
Jing Bian,
Margaret Cam,
Jeffrey Schlom,
Sofia R. Gameiro

Affiliations

Kristin C. Hicks: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Paul L. Chariou: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Yohei Ozawa: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Christine M. Minnar: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Karin M. Knudson: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Thomas J. Meyer: CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute, National Institutes of Health
Jing Bian: CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute, National Institutes of Health
Margaret Cam: CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, National Cancer Institute, National Institutes of Health
Jeffrey Schlom: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Sofia R. Gameiro: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health

DOI: https://doi.org/10.1038/s41467-021-25393-x
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 18

Abstract

Read online

The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour microenvironment that favours tumour resolution.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal